---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-069211"
form_type: "8-K"
ticker: "RGNX"
cik: "0001590877"
company_name: "REGENXBIO Inc."
filed_at: "2025-05-12T23:59:59+00:00"
generated_at: "2026-05-21T23:39:22.172027+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# REGENXBIO Q1 net income $6.1M; revenue up 471% to $89M on Nippon Shinyaku deal

## Summary
- Net income $6.1M ($0.12 EPS) vs net loss $63.3M ($1.38 loss) in Q1 2024.
- Revenue $89.0M (vs $15.6M) driven by $71.8M license revenue from Nippon Shinyaku partnership.
- Cash $272.7M; operations funded into 2H 2026; guidance excludes milestone payments and PRV.
- RGX-202 Duchenne pivotal trial >50% enrolled; BLA submission on track for mid-2026.
- FDA expected to accept BLA for clemidsogene lanparvovec (RGX-121) in May; potential 2025 approval.

## SEC filing metadata
- accession: 0000950170-25-069211
- form_type: 8-K
- ticker: RGNX
- cik: 0001590877
- company_name: REGENXBIO Inc.
- filed_at: 2025-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590877/000095017025069211/0000950170-25-069211-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590877/000095017025069211/rgnx-20250512.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-069211
- JSON: https://secwatch.observer/filing/0000950170-25-069211.json
- Plain text: https://secwatch.observer/filing/0000950170-25-069211.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.